126 related articles for article (PubMed ID: 33785652)
1. Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition.
Carnevalli LS; Taylor MA; King M; Coenen-Stass AML; Hughes AM; Bell S; Proia TA; Wang Y; Ramos-Montoya A; Wali N; Carroll D; Singh M; Moschetta M; Gutierrez PM; Gardelli C; Critchlow SE; Klinowska T; Fawell SE; Barry ST
Mol Cancer Ther; 2021 Jun; 20(6):1080-1091. PubMed ID: 33785652
[TBL] [Abstract][Full Text] [Related]
2. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
3. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.
Kaneda MM; Cappello P; Nguyen AV; Ralainirina N; Hardamon CR; Foubert P; Schmid MC; Sun P; Mose E; Bouvet M; Lowy AM; Valasek MA; Sasik R; Novelli F; Hirsch E; Varner JA
Cancer Discov; 2016 Aug; 6(8):870-85. PubMed ID: 27179037
[TBL] [Abstract][Full Text] [Related]
4. PI3Kγ is a molecular switch that controls immune suppression.
Kaneda MM; Messer KS; Ralainirina N; Li H; Leem CJ; Gorjestani S; Woo G; Nguyen AV; Figueiredo CC; Foubert P; Schmid MC; Pink M; Winkler DG; Rausch M; Palombella VJ; Kutok J; McGovern K; Frazer KA; Wu X; Karin M; Sasik R; Cohen EE; Varner JA
Nature; 2016 Nov; 539(7629):437-442. PubMed ID: 27642729
[TBL] [Abstract][Full Text] [Related]
5. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
6. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.
Lauret Marie Joseph E; Kirilovsky A; Lecoester B; El Sissy C; Boullerot L; Rangan L; Marguier A; Tochet F; Dosset M; Boustani J; Ravel P; Boidot R; Spehner L; Haicheur-Adjouri N; Marliot F; Pallandre JR; Bonnefoy F; Scripcariu V; Van den Eynde M; Cornillot E; Mirjolet C; Pages F; Adotevi O
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230108
[TBL] [Abstract][Full Text] [Related]
7. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
8. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
9. PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer.
Curcio C; Mucciolo G; Roux C; Brugiapaglia S; Scagliotti A; Guadagnin G; Conti L; Longo D; Grosso D; Papotti MG; Hirsch E; Cappello P; Varner JA; Novelli F
J Exp Clin Cancer Res; 2024 Jun; 43(1):157. PubMed ID: 38824552
[TBL] [Abstract][Full Text] [Related]
10. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
Bissonnette RP; Cesario RM; Goodenow B; Shojaei F; Gillings M
BMC Cancer; 2021 Aug; 21(1):969. PubMed ID: 34461854
[TBL] [Abstract][Full Text] [Related]
11. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
[TBL] [Abstract][Full Text] [Related]
12. PI3Kγ Activates Integrin α
Foubert P; Kaneda MM; Varner JA
Cancer Immunol Res; 2017 Nov; 5(11):957-968. PubMed ID: 28963139
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
14. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression.
Joshi S; Liu KX; Zulcic M; Singh AR; Skola D; Glass CK; Sanders PD; Sharabi AB; Pham TV; Tamayo P; Shiang D; Dinh HQ; Hedrick CC; Morales GA; Garlich JR; Durden DL
Mol Cancer Ther; 2020 Mar; 19(3):755-764. PubMed ID: 31974273
[TBL] [Abstract][Full Text] [Related]
15. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
16. PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.
Sai J; Owens P; Novitskiy SV; Hawkins OE; Vilgelm AE; Yang J; Sobolik T; Lavender N; Johnson AC; McClain C; Ayers GD; Kelley MC; Sanders M; Mayer IA; Moses HL; Boothby M; Richmond A
Clin Cancer Res; 2017 Jul; 23(13):3371-3384. PubMed ID: 28003307
[No Abstract] [Full Text] [Related]
17. Modified Jian-pi-yang-zheng decoction inhibits gastric cancer progression via the macrophage immune checkpoint PI3Kγ.
Yuan M; Zou X; Liu S; Xu X; Wang H; Zhu M; Xie X; Wang H; Wu J; Sun Q
Biomed Pharmacother; 2020 Sep; 129():110440. PubMed ID: 32768942
[TBL] [Abstract][Full Text] [Related]
18. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
[TBL] [Abstract][Full Text] [Related]
19. Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy.
Nagaoka K; Shirai M; Taniguchi K; Hosoi A; Sun C; Kobayashi Y; Maejima K; Fujita M; Nakagawa H; Nomura S; Kakimi K
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093158
[TBL] [Abstract][Full Text] [Related]
20. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
